ACY1 Downregulation Enhances the Radiosensitivity of Cetuximab-Resistant Colorectal Cancer by Inactivating the Wnt/β-Catenin Signaling Pathway

SIMPLE SUMMARY: Cetuximab, which can be used in combination with other chemotherapies, is widely used as a standard of care treatment in the majority of advanced colorectal cancer (CRC) patients. However, the treatment of cetuximab-resistant CRC remains a major problem. The study was to assess the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Shan, Wulin, Dai, Chunyang, Zhang, Huanhuan, Han, Dan, Yi, Qiyi, Xia, Bairong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688869/
https://www.ncbi.nlm.nih.gov/pubmed/36428796
http://dx.doi.org/10.3390/cancers14225704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688869/
https://www.ncbi.nlm.nih.gov/pubmed/36428796
http://dx.doi.org/10.3390/cancers14225704

Ejemplares similares